Provention Bio | Investor Relations

Investor Alerts

Sep 26, 2019

Sean Doherty Joins Provention Bio Board of Directors

- T1D Fund Executive Chairman and Former Bain Capital Managing Director Brings Extensive Financial Expertise and Deep Knowledge of Therapeutics Landscape -

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Sean Doherty...
Sep 25, 2019

Provention Bio to Present at the 2019 Cantor Global Healthcare Conference

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at...
Sep 24, 2019

Provention Bio Reiterates Regulatory Strategy for PRV-031 and Announces Completion of Follow-on Financing

- FDA Meeting Expected in Q4 2019 and BLA Submission for PRV-031 (teplizumab) Targeted for Q4 2020 -

Provention Bio, Inc., (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reiterated its regulatory strategy...
Sep 18, 2019

Provention Bio Announces Pricing of $40 Million Public Offering of Common Stock

Provention Bio, Inc., (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing of its previously...
Sep 18, 2019

Provention Bio Announces Proposed Public Offering of Common Stock

Provention Bio, Inc., (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has commenced an...
Sep 5, 2019

Provention Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at...
Aug 20, 2019

Provention Bio Announces Key Addition to its Leadership Team

- Appoints Dr. Sherron Kell as SVP of Clinical Development and Program Lead for PRV-031 (Teplizumab) -

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Sherron Kell,...
Aug 8, 2019

Provention Bio Initiates Phase 1b/2a PREVAIL Clinical Trial Evaluating PRV-3279 in Lupus

-Bispecific Diabody Designed to Intercept B-Cell Mediated Autoimmune Diseases-

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it has dosed the first...
Aug 6, 2019

Provention Bio Reports Second Quarter 2019 Financial Results

PRV-031 Granted Breakthrough Therapy Designation for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the second...
Aug 5, 2019

Provention Bio Announces Breakthrough Therapy Designation for Teplizumab (PRV-031) for the Prevention or Delay of Clinical Type 1 Diabetes in At-Risk Individuals

Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the U.S. Food and Drug...
Jun 13, 2019

Provention Bio Announces Termination of Public Offering of Common Stock

Provention Bio, Inc. (Nasdaq: PRVB) announced today that it has terminated the public offering of common stock previously announced on June 10, 2019. The termination results from an assessment by...
Jun 10, 2019

Provention Bio Announces Proposed Public Offering of Common Stock

Provention Bio, Inc. (Nasdaq: PRVB) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a registered...
Jun 9, 2019

A Single Course of Provention's PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least Two Years

Results from the NIH-Sponsored "At-Risk" Study Published in The New England Journal of Medicine and Presented at the American Diabetes Association Annual Meeting

Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that results from the National...
May 8, 2019

Provention Bio Reports First Quarter 2019 Financial Results

PROTECT Pivotal Phase 3 Clinical Study Initiated in Patients with Recent Onset Type 1 Diabetes

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the first...
May 8, 2019

Provention Bio Announces Top-Line Results from its Phase 1b PULSE Clinical Trial of PRV-300 in Patients with Moderate-to-Severe Ulcerative Colitis

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced preliminary top-line results from...
Apr 24, 2019

Provention Bio Completes Enrollment of Phase 2a PRINCE Clinical Trial with PRV-6527 in Patients with Moderate to Severe Crohn's Disease

- Top-line Data Anticipated in the Fourth Quarter of 2019 -

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has completed the...
Apr 9, 2019

Provention Bio Initiates Phase 3 PROTECT Clinical Trial with PRV-031 (Teplizumab) in Patients with Recent Onset Type 1 Diabetes

Pivotal Study to Evaluate Potential of Anti-CD3 Monoclonal Antibody to Intercept Type 1 Diabetes

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has dosed the first...
Apr 2, 2019

Provention Bio Announces Key Additions to its Senior Management Team

Strengthens Leadership Team with Appointment of Douglas Jacobstein, M.D. as V.P. of Clinical Development and Alex Rabiee as V.P. of Business Development

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Douglas...
Mar 28, 2019

Provention Bio Appoints Jeffrey Bluestone, PhD, to Board of Directors

Dr. Bluestone is a World-renowned Expert and Academic Leader in Immune Tolerance Research

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Jeffrey...
Mar 19, 2019

Provention Bio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

Plan to Initiate PROTECT Study for PRV-031 (teplizumab) in T1D Patients in Q2

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the fourth...
Mar 12, 2019

Provention Bio to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Tuesday, March 19, 2019

Provention Bio, Inc. (Nasdaq:PRVB), a clinical-stage biopharmaceutical company focused on preventing and intercepting immune-mediated diseases, announced today it will host a conference call and...
Feb 13, 2019

Provention Bio To Present at 8th Annual Leerink Partners Global Healthcare Conference

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases, announced...
Jan 28, 2019

Provention Bio Receives Notice of Allowance from United States Patent and Trademark Office for Patent on Multi-Strain Coxsackievirus B Vaccine for Preventing or Treating Type 1 Diabetes (T1D)

Provention is currently developing PRV-101 as a polyvalent vaccine for acute coxsackie virus infection and to potentially prevent the onset of T1D

Provention Bio, Inc. (Nasdaq:PRVB), a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases, announced...
Jan 3, 2019

Provention Bio Announces Publication in "Expert Review of Vaccines" Describing the Scientific Rationale for Developing a Vaccine for Type 1 Diabetes by Targeting Coxsackievirus B

Provention is currently developing PRV-101 as a vaccine for acute coxsackie infection and to potentially prevent the onset of T1D

Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases, announced...
Nov 28, 2018

Provention Bio Joins the C-Path Type 1 Diabetes (T1D) Consortium

Provention Bio, Inc. (Nasdaq:PRVB), a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing...

Show per page

news releases